Intuitive Surgical experienced a significant drop in its stock value, falling as much as 13% in after-market trading. This decline was attributed to a slowdown in the growth of its da Vinci surgical robot procedures, which reached its weakest pace in four years. The company's guidance for future procedure growth remained unchanged, failing to alleviate investor concerns.

Several factors are believed to be contributing to this deceleration. Changes related to the Affordable Care Act (ACA) may be impacting hospital budgets and elective surgery rates. Additionally, the increasing popularity of GLP-1 medications, such as Ozempic and Wegovy, is leading some patients to postpone or cancel surgical interventions, including those that would utilize Intuitive Surgical's robotic systems.

The company's performance, particularly the slowing procedure growth, has raised questions about its near-term outlook. Investors are closely watching how Intuitive Surgical navigates these challenges and adapts to the evolving healthcare landscape.